Phase Appropriate GMPs for Cell and Gene Therapy Compliance with Troy Fugate and Melissa Schneider

Join us for an informative discussion with pharmaceutical and medical device experts, Troy Fugate and Melissa Schneider from Compliance Insight, as they delve into the world of cell and gene therapy compliance. With over 60 years of combined experience, Troy and Melissa provide valuable insights on the phase-appropriate implementation of Good Manufacturing Practices (GMPs) in this rapidly growing industry.

Discover key considerations for controlling raw materials, methods, processes, and data integrity. Gain insights into the challenges and successes along the development path including R&D, Pre-clinical studies, Process and Method Validation & more. Explore the DNA of GMP implementation and learn how to create a roadmap for success in this evolving landscape.

==========================

For more, visit us at https://www.compliance-insight.com

Compliance Insight is a leading FDA regulatory and quality assurance consulting firm that offers a range of services to assist companies in navigating the complexities of FDA regulations. With their in-depth knowledge and expertise, Compliance Insight provides invaluable guidance and support to ensure compliance with FDA requirements.

One of their key services is assisting companies with the 510(k) process. They understand the intricacies involved in preparing and submitting 510(k) applications for medical devices. Compliance Insight helps clients gather the necessary data, conduct thorough reviews, and ensure the application meets all regulatory standards, streamlining the path to FDA clearance.

In addition, Compliance Insight has extensive experience in the emerging field of cell and gene therapies. They offer specialized guidance on navigating the unique regulatory landscape for these innovative therapies, helping clients understand and meet FDA requirements to bring their life-changing treatments to market.

Another area of expertise for Compliance Insight is providing assistance with 483 and Warning Letter response and remediation. In the event of an FDA inspection resulting in observations or deficiencies (captured in Form 483), Compliance Insight supports companies in developing comprehensive and effective responses. Their team works closely with clients to address each observation, develop appropriate corrective actions, and ensure timely and compliant resolution.

Whether it's navigating the 510(k) process, advancing cell and gene therapies, addressing 483 observations, product recalls, or more; Compliance Insight's services encompass comprehensive regulatory support to help companies achieve and maintain FDA compliance, fostering successful product development and market approval.